




RealRate

PHARMACEUTICAL 2022

Dogwood Therapeutics Inc
Rank 235 of 471



RealRate

The First AI Rating Agency

www.realrate.ai



PHARMACEUTICAL 2022

Dogwood Therapeutics Inc Rank 235 of 471

The relative strengths and weaknesses of Dogwood Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Dogwood Therapeutics Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 88% points. The greatest weakness of Dogwood Therapeutics Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 74% points.

The company's Economic Capital Ratio, given in the ranking table, is 291%, being 16% points above the market average of 275%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	15,777	Assets	15,777
Cost of Goods Sold	0	Liabilities	1,276
Intangible Assets	0	Expenses	15,641
Liabilities, Current	1,276	Revenues	0
Liabilities, Non-Current	0	Stockholders Equity	14,501
Other Assets	0	Net Income	-15,960
Other Compr. Net Income	0	Comprehensive Net Income	-15,960
Other Expenses	0	BaseVar	16,506
Other Liabilities	0	ECR before LimitedLiability	184%
Other Net Income	-319	Economic Capital Ratio	291%
Other Revenues	0		
Property and Equipment	0		
Research and Development	10,796		
Selling, General and Administrative Expense	4,845		